Coya Therapeutics recently announced the results from its POC open-label study evaluating COYA 301, a low-dose IL-2 treatment, in patients with Alzheimer’s disease. The trial showed promising results, with statistically significant improvements in cognition on the Mini-Mental State Examination (MMSE) scale, improved Treg population and functionality, and lower levels of pro-inflammatory biomarkers at the end of the treatment regimen. Considering the company’s ability to replicate encouraging res ....
05 Jun 2023
Coya Therapeutics (NASDAQ: COYA) - Company Update
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Coya Therapeutics (NASDAQ: COYA) - Company Update
Coya Therapeutics recently announced the results from its POC open-label study evaluating COYA 301, a low-dose IL-2 treatment, in patients with Alzheimer’s disease. The trial showed promising results, with statistically significant improvements in cognition on the Mini-Mental State Examination (MMSE) scale, improved Treg population and functionality, and lower levels of pro-inflammatory biomarkers at the end of the treatment regimen. Considering the company’s ability to replicate encouraging res ....